Institutional Ownership
Agomab Therapeutics NV
CUSIP 00860C102SPONSORED ADSQ1 2026
13D / 13G Filings
1
Schedule 13D/13G on record
Beneficial Filers
1
Distinct reporting persons
Largest Stake
10.6%
Max % of class reported
Institutional Holders
32
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
1 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Lsp 7 Cooperatieve U.A. | 13D | 10.6% | — | SEC |
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Eqt Fund Management S.A R.L. | 5.14M | $53.94M |
| 2 | Sanofi | 2.78M | $29.19M |
| 3 | Cormorant Asset Management, LP | 2.47M | $25.86M |
| 4 | Tcg Crossover Management, LLC | 2.05M | $21.54M |
| 5 | Federated Hermes, Inc. | 1.62M | $16.97M |
| 6 | Casdin Capital, LLC | 1.55M | $16.26M |
| 7 | Andera Partners | 1.54M | $16.14M |
| 8 | Fmr LLC | 1.46M | $15.30M |
| 9 | Nantahala Capital Management, LLC | 1.20M | $12.85M |
| 10 | Aberdeen Group PLC | 707.7K | $7.42M |